Immunogenic Cell Death by the Novel Topoisomerase I Inhibitor TLC388 Enhances the Therapeutic Efficacy of Radiotherapy

SIMPLE SUMMARY: This study aims to evaluate the induction of immunogenic cell death (ICD) for anticancer immunity by the novel topoisomerase I inhibitor lipotecan. These results show that lipotecan can remarkably elicit ICD and increase tumor immunogenicity, which promotes the therapeutic efficacy o...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Kevin Chih-Yang, Chiang, Shu-Fen, Yang, Pei-Chen, Ke, Tao-Wei, Chen, Tsung-Wei, Hu, Ching-Han, Huang, Yi-Wen, Chang, Hsin-Yu, Chen, William Tzu-Liang, Chao, K. S. Clifford
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998596/
https://www.ncbi.nlm.nih.gov/pubmed/33799527
http://dx.doi.org/10.3390/cancers13061218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998596/
https://www.ncbi.nlm.nih.gov/pubmed/33799527
http://dx.doi.org/10.3390/cancers13061218

Ejemplares similares